Finance

Lists
Why is SABS up 2,31%?
Dive Deeper
SABS:NASDAQ
SAB Biotherapeutics Inc
3,10 USD
+2,31%
(+0,070) 1D
3,09 USD
-0,33% (-0,010)
After hours
Closed: 9-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
3,10 USD
High
3,18 USD
Low
3,05 USD
Mkt. cap
282,06 млн
Avg. vol.
642,58 миң
Volume
0,00
52-wk high
5,15 USD
52-wk low
2,44 USD
EPS
-0,63 USD
Beta
0,67
Shares outstanding
90,09 млн
No. of employees
86
Open
3,10 USD
High
3,18 USD
Low
3,05 USD
Mkt. cap
282,06 млн
Avg. vol.
642,58 миң
Volume
0,00
52-wk high
5,15 USD
52-wk low
2,44 USD
EPS
-0,63 USD
Beta
0,67
Shares outstanding
90,09 млн
No. of employees
86
News stories
From web sources and news partners
About SAB Biotherapeutics Inc
CEO-
Employees86
Founded2014
HeadquartersМайами Бич, Флорида, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websitesab.bio
Analyst ratings
Based on 4 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current 3,10 USD
15,00 USD (+383,87%)
Average
13,25 USD (+327,42%)
Lowest
11,00 USD (+254,84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Buy
Reiterated
14,00 USD
+351,6%
11/06/2026
Samantha Semenkow
Citi
Buy
Maintained
11,00 USD
+254,8%
11/05/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
15,00 USD
+383,9%
11/05/2026
Eliana Merle
Barclays
Buy
Maintained
13,00 USD
+319,4%
11/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
10,00 USD
+222,6%
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
16,00 USD
+416,1%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
6,00 USD
+93,5%
06/16/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
14,00 USD
+351,6%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
11,00 USD
+254,8%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
15,00 USD
+383,9%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
13,00 USD
+319,4%
04/02/2026
Michael Yee
UBS
Buy
Maintained
7,00 USD
+125,8%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
-
-
-
-
Cost of goods sold
9,73 млн
13,40 млн
16,17 млн
18,08 млн
Cost of revenue
9,73 млн
13,40 млн
16,17 млн
18,08 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,04 млн
6,60 млн
7,20 млн
7,82 млн
Operating expense
6,04 млн
6,60 млн
7,20 млн
7,82 млн
Total operating expenses
15,77 млн
20,00 млн
23,38 млн
25,90 млн
Operating income
-15,77 млн
-20,00 млн
-23,38 млн
-25,90 млн
Other non operating income
-1,73 млн
144,40 миң
-761,00 миң
1,99 млн
EBT including unusual items
-16,86 млн
-18,87 млн
-22,49 млн
-22,30 млн
EBT excluding unusual items
-16,86 млн
-18,87 млн
-22,49 млн
-22,30 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16,86 млн
-18,87 млн
-22,49 млн
-22,30 млн
Net profit margin
-
-
-
-
Earnings per share
-0,41
-
-0,28
-0,26
Interest and investment income
700,74 миң
1,05 млн
1,71 млн
1,61 млн
Interest expense
-63,46 миң
-62,74 миң
-62,00 миң
-
Net interest expenses
637,28 миң
984,45 миң
1,65 млн
1,61 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,01 млн
-19,25 млн
-22,54 млн
-25,08 млн
Gain or loss from assets sale
-
-
-
-66,00 миң
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору